Haemonetics (HAE) Jumps As Citi Hikes Price Target To $123
Haemonetics (HAE) stock rose 17.46% after Citigroup upgraded it to Buy with a $123 price target, up from $92. The upgrade follows a new supply agreement with CSL, which Citi expects to boost earnings. HAE reported Q1 revenue of $339.4M, net income of $33.0M, and free cash flow of $44.4M. The stock trades at a P/E of 50 and price-to-sales of 3.5.
How this was made
The 30-second read
Why it matters
The article frames the rally as a Citi-driven re-rating tied to a CSL non-exclusive supply agreement, with an explicit EPS sensitivity narrative (share recapture translating into EPS). It also flags upcoming Q2 FY2027 results as the next validation point.
Market read
Traders get a near-term catalyst (analyst upgrade with a raised target) plus a scheduled earnings checkpoint, which can drive momentum and positioning decisions.
What to watch
The article highlights meaningful leverage (debt above $1.1B) and near-term cash drain from Vivasure milestone payments, which could cap upside if margins or cash flow disappoint in the upcoming quarter.
Background
Haemonetics is described as integrating Vivasure and operating in a high-margin medical technology business, with the stock recently trading in a $104 to $109 range before the jump.
Ticker impact
Citi upgraded Haemonetics to Buy and raised its price target to $123, linking the thesis to a new non-exclusive CSL supply agreement.
Likely upward bias as traders price in Citi’s higher EPS expectations tied to CSL supply recapture, with follow-through dependent on volume and Q2 results.
The article attributes the move to a same-day analyst upgrade with a specific EPS sensitivity to CSL share recapture, and notes the stock’s sharp gap and continued strength into the high teens/low $120s.
Market effects
Positive read-through for medical technology and vascular closure supply-chain narratives, though the article is single-name focused.
No clear regional macro linkage beyond US equity sentiment.
Limited, as the catalyst is company-specific (Citi upgrade and CSL supply agreement).
Counterpoint
The initial reaction is described as occurring on below-average volume, so the move could fade if follow-through volume does not materialize before earnings.
Key entities
- companyHaemonetics Corporation
Subject of the article, with shares jumping on a Citi upgrade and a CSL supply agreement-linked earnings outlook.
- analyst_firmCitigroup
Upgraded HAE from Neutral to Buy and raised its price target to $123.
- companyCSL
Partner in a new non-exclusive supply agreement cited as the earnings upside driver.
- companyOrchestra BioMed
Recipient of a $6.1M milestone payment mentioned in the Vivasure integration context.
